Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Post by toinv261on Nov 07, 2016 2:09pm
162 Views
Post# 25433346

Fun speculation

Fun speculationWell by next Tuesday we should know something about RVX, Zenith or both and we may know the results of the USA election by tomorrow.  As a Canadian I have been fascinated by the US election (to say the least) so I will be watching the “entire show” tomorrow night.
 
So just for some fun speculation on the RVX/Zenith side of things what do we know?
  1. We know that starting around Sept 13th share price and volume moved up dramatically.
  2. We know that the share price is hanging in around $2 give or take.
  3. We know that at the NYC R & R Don seemed confident about a new licensing deal.
  4. We know that the zen3694 trial on mCRPC won’t be complete until Q3 2017 (perhaps since it is not a double blind trial we’ll see results sooner???). If so, I hope results are interesting to Pfizer.
  5. We have an idea that the futility analysis of BETonMACE will not be stated until Q3 2017.
  6. So, on the science side of things I don’t think we are going to hear anything soon.
 
From my perspective there is a lot of exciting science happening at these companies. I haven’t seen any interest from BP at this stage but I would guess that BP has their eyes on this little company. As Don stated both companies are for sale at the right price.
 
My guess for Nov 15th or before is a new licensing deal. Depending on the partner it could have very significant implications.
 
Anyway, just rambling out of frustration in this information vacuum.
 
Good luck to our USA posters. I hope you get the best of 2 what appear to be bad choices in your election.
 
I’m having problems with Stockhouse hanging again on my MAC Google Chrome…frustrating.
Cheers
Toinv
 
 
Bullboard Posts